Nomifensine

Nomifensine

Clinical data
Routes of administration	Oral
ATC code	N06AX04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life	1.5-4 hours
Excretion	Kidney (88%) within 24 hours
Identifiers
IUPAC name (±)-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine
CAS Number	24526-64-5 N
PubChem CID	4528
DrugBank	DB04821 Y
ChemSpider	4371 Y
UNII	1LGS5JRP31
ChEBI	CHEBI:116225 Y
ChEMBL	ChEMBL273575 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H18N2
Molar mass	238.328 g/mol
3D model (JSmol)	Interactive image
SMILES NC1=CC=CC2=C1CN(C)CC2C3=CC=CC=C3
InChI InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3 Y Key:XXPANQJNYNUNES-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Nomifensine
Articles
Most recent articles on Nomifensine Most cited articles on Nomifensine Review articles on Nomifensine Articles on Nomifensine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nomifensine Images of Nomifensine Photos of Nomifensine Podcasts & MP3s on Nomifensine Videos on Nomifensine
Evidence Based Medicine
Cochrane Collaboration on Nomifensine Bandolier on Nomifensine TRIP on Nomifensine
Clinical Trials
Ongoing Trials on Nomifensine at Clinical Trials.gov Trial results on Nomifensine Clinical Trials on Nomifensine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nomifensine NICE Guidance on Nomifensine NHS PRODIGY Guidance FDA on Nomifensine CDC on Nomifensine
Books
Books on Nomifensine
News
Nomifensine in the news Be alerted to news on Nomifensine News trends on Nomifensine
Commentary
Blogs on Nomifensine
Definitions
Definitions of Nomifensine
Patient Resources / Community
Patient resources on Nomifensine Discussion groups on Nomifensine Patient Handouts on Nomifensine Directions to Hospitals Treating Nomifensine Risk calculators and risk factors for Nomifensine
Healthcare Provider Resources
Symptoms of Nomifensine Causes & Risk Factors for Nomifensine Diagnostic studies for Nomifensine Treatment of Nomifensine
Continuing Medical Education (CME)
CME Programs on Nomifensine
International
Nomifensine en Espanol Nomifensine en Francais
Business
Nomifensine in the Marketplace Patents on Nomifensine
Experimental / Informatics
List of terms related to Nomifensine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nomifensine (Merital, Alival) is a norepinephrine-dopamine reuptake inhibitor developed by a team at Hoechst AG in the 1960s. The drug was test marketed in the United States by Hoechst AG (now Sanofi-Aventis), i.e. a drug that increases the amount of synaptic norepinephrine and dopamine available to receptors by blocking the dopamine and norepinephrine reuptake transporters. This is a mechanism of action shared by some recreational drugs like cocaine and the medication Tametraline (see DRI). Research showed that the (S) isomer is responsible for activity. The drug was an effective antidepressant, without sedative effects. Nomifensine did not interact significantly with alcohol and lacked anticholinergic effects. No withdrawal symptoms were seen after 6 months treatment. The drug was however considered not suitable for agitated patients as it presumably made agitation worse. In January 1986 the drug was withdraw by its manufacturers for safety reasons.

Some case reports in the 1980s suggested that there was potential for psychological dependence on nomifensine, typically in patients with a history of stimulant addiction, or when the drug was used in very high doses (400–600 mg per day).

In a 1989 study it has been investigated for use in treating adult ADHD and proven successful. In a 1977 study it has not proven of benefit in advanced parkinsonism, except for depression associated with the parkinsonism.

Clinical uses

Nomifensine was investigated for use as an antidepressant in the 1970s, and was found to be a useful antidepressant at doses of 50–225 mg per day, both motivating and anxiolytic.

Side effects

During treatment with nomifensine there were relatively few adverse effects mainly renal failure, paranoid symptoms, drowsiness or insomnia, headache, and dry mouth. Side effects affecting the cardiovascular system included tachycardia and palpitations, but nomifensine was significantly less cardiotoxic than the standard triciclyc antidepressants.

Due to the risk of a risk of haemolytic anaemia, the U.S. Food and Drug Administration (FDA) withdrew approval for nomifensine on March 20, 1992. Nomifensine has subsequently been withdrawn from the Canadian and UK markets as well. Some deaths were linked to immunohaemolytic anemia caused by this compound although the mechanism remained unclear.

In 2012 structure–affinity relationship data (compare SAR) were published.

Synthesis

Nomifensine synthesis:

See also

• Amineptine

References

Template:Antidepressants Template:Stimulants